High Dose Dexamethasone versus Prednisone as First Line Therapy in Newly diagnosed Immune Thrombocytopenic Purpura in Children

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202403843973020

Enrollment

Registered

2024-03-27

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics

Interventions

prednisone

dexamethasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 1–18 years with newly diagnosed primary ITP before starting any treatment having platelet count < 30,000 /µL

Exclusion criteria

Exclusion criteria: 1-Patients with secondary ITP including leukemia, drugs, lupus erythematous, hepatitis C, anti-phospholipid syndrome. 2-Ptaients with ITP who received any treatment.

Design outcomes

Primary

Measure	Time frame
an early response, initial response, and durable response and remission rates in both groups.	—

Secondary

Measure	Time frame
bleeding score and glucocorticoid-related side effects	—

Countries

Egypt

Contacts

Public ContactAdel Abd El Haleim Hagag

Professor of Pediatrics

adelhagag20@yahoo.com+201005020768

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026